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POPULAR SCIENCE SUMMARY OF THE THESIS 
Uveal melanoma is a rare malignant tumor in the eye which affects 5-10 
persons per million inhabitants per year. People with northern appearance 
have a higher risk of the disease, but the correlation to ultraviolet exposure is 
not as certain as it is to malignant melanoma in the skin. The age of 
diagnosis is generally around 60 years old and it is equally common in males 
and females. Uveal melanoma rarely affects children. Unfortunately, the 
cancer has spread to other organs in up to one half of patients within 15 
years from diagnosis. After the tumor has spread, most patients die within a 
year. 
 In the late 60’s local radiation treatment (brachytherapy) 
became more and more available as an alternative treatment to removal of 
the entire eye. It meant a possibility for the patient to keep the eye and 
preserve vision. Brachytherapy gained even more popularity as a beneficial 
treatment option for medium sized tumors when it was shown that these 
patients have the same survival rate as patients who have the eye removed. 
In Sweden we use the radionuclide ruthenium-106 for tumors thinner than 6-
7 mm, and iodine-125 for tumors 7-10 mm thick. Tumors thicker than 10 
mm are treated with eye removal. Between 1979 and 1999 only ruthenium-
106 was available, and thus there are some tumors thicker than 7 mm that 
have been treated with ruthenium-106 in the past. 
In paper I we evaluated the radiation dose rate, i.e. radiation 
dose per time unit in ruthenium-106 brachytherapy. We investigated if there 
was an association between dose rate and the risk of having to remove the 
eye after brachytherapy, due to insufficient effect of the treatment/tumor 
relapse or due to a blind and/or painful eye because of radiation damage to 
normal ocular tissue surrounding the tumor. We found no such correlation.  
In paper II we compared ruthenium-106 and iodine-125 for the 
treatment of tumors 5.5 mm or thicker. We compared matched subgroups 
and found no difference in risk of dying from the melanoma, but the patients 
treated with ruthenium-106 had a higher risk of needing another round of 
brachytherapy due to insufficient effect of the treatment or tumor recurrence. 
We thereby confirmed that iodine-125 is preferable for thicker tumors, in 
accordance with today’s treatment regime.  
In paper III we investigated whether there are any gender 
differences regarding tumor characteristics, effect of treatment or patient 
survival. We found no differences between men and women that would 
indicate that the patient’s gender should be considered when handling 
patients with uveal melanoma.  
In paper IV we analyzed whether radiation dose or dose rate in 
brachytherapy with ruthenium-106 and iodine-125 correlated to the risk of 





Uveal melanomas constitute melanomas arising from the choroid, the ciliary 
body or the iris, and in adults stands for the most common primary 
malignant intraocular tumor. It has a high risk of metastatic spread followed 
by inevitable death, and unfortunately the prognosis has not improved over 
the last decades.  
In the beginning the only considerable treatment was 
enucleation, i.e. removal of the entire eye. However, brachytherapy has since 
the 70’s become the primary treatment for medium sized tumors, and the 
survival rate has been shown to be equal compared to primary enucleation.  
The aim of our studies included in this thesis was to 
investigate the efficacy of today’s brachytherapy treatment regime and if any 
differences in ocular or patient survival could be found considering different 
brachytherapy aspects. When investigating only ruthenium-106 
brachytherapy, no association was found between high or low dose rate and 
the risk of secondary enucleation, i.e. enucleation due to extensive unwanted 
side effects, insufficient treatment effect on the tumor or tumor relapse. In 
further analysis with both ruthenium-106 and iodine-125 brachytherapy 
included in the study and the risk of tumor related mortality considered, 
there was no statistical difference in outcome related to either dose or dose 
rate applied and we found no negative consequences for patients that 
received lower dose and dose rates than intended.  
As there is a gender difference in survival outcome for some 
cancers, we investigated this issue regarding uveal melanoma, but no 
differences could be found indicating this should be a factor to consider 
when planning treatment.  
Ruthenium-106 brachytherapy is generally used throughout 
Europe. In Sweden, iodine-125 for larger medium sized tumors became 
available 20 years after ruthenium-106 brachytherapy had begun. We 
therefore had a great opportunity to analyze the larger tumors treated with 
ruthenium-106 in the earlier years and compare them to same size tumors 
treated with iodine-125. There was no difference in survival between 
matched groups, but ruthenium-106-treated patients had a significantly 
higher risk of needing retreatment, thus making iodine-125 the preferred 
nuclide for thicker tumors.  
In conclusion gender is not a factor that needs considering 
when planning treatment for uveal melanoma. Treatment with brachytherapy 
is both safe and effective within the current recommended doses and dose 
rates. Our findings suggest that lower doses and dose rates still would be 
adequate, and this should be investigated further. The current protocol for 
radioisotope selection based on tumor thickness also seems adequate for the 
best possible ocular and survival outcome. 
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1 INTRODUCTION  
Uveal melanoma is the most common primary malignant intraocular tumor, with a high risk 
for metastasis and tumor-related death.(A. D. Singh, Turell, & Topham, 2011) The tumor’s 
tissue of origin - the uvea - consists of three anatomical structures: the choroid, the ciliary 
body and the iris. The melanoma originates from melanocytes that normally occur in these 
structures, and spreads hematogenously predominantly to the liver. Historically, the primary 
treatment was surgical removal of the entire eye - enucleation . Enucleation is still the 
primary treatment for large tumors, but for small to medium-sized tumors, eye-preserving 
local radiation treatment - plaque brachytherapy – has been the standard treatment for four 
decades (American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic 
address & Committee, 2014) without negative survival consequences.(Diener-West et al., 
2001b) Brachytherapy treatment recommendations generally have been based on consensus, 
as studies on dosimetric issues have been low in number. Patient and ocular factors that might 





















2 LITERATURE REVIEW 
2.1 UVEAL MELANOMA 
2.1.1 Anatomy 
Uveal melanoma is located in the iris and ciliary body in 4 % and 6 % of cases respectively. 
The absolute majority, 90 %, originate from the choroid.(Kaliki & Shields, 2017) The 
choroidal melanomas are mostly dome shaped or mushroom-shaped and greyish in tone. Iris 
melanomas are mostly located inferiorly.(Shields, Kaliki, Shah, et al., 2012) 
 
Figure 1. Locations of uveal melanoma. Used with permission of Mayo Foundation for 
medical education and research. All rights reserved.  
The tumors are categorized as small, medium or large in size by a widely 
accepted set of criteria established by the Collaborative Ocular Melanoma Study group 
(COMS) in the late 1980’s. Small tumors are defined as < 2.5 mm in height and >5 mm in 
diameter. Medium sized tumors are 2.5-10 mm thick and a maximum of 16 mm in diameter.  
Tumors exceeding 10 mm in thickness, or 16 mm in diameter at the base are defined as 
large.("Design and methods of a clinical trial for a rare condition: the Collaborative Ocular 




quarter of the choroid but still is not thicker than 5 mm it is referred to as a diffuse 
melanoma.(Reese & Howard, 1967) Men have been reported to have a larger and more 
posterior located tumors than women.(B. E. Damato & Coupland, 2012) 
 
 
Figure 2. Typical appearance of a choroidal melanoma. Picture from patient at St. Erik Eye 
Hospital.  
Histologically, uveal melanoma consists of tumor cells, fibroblasts, 
macrophages, lymphocytes and blood vessels. There are two types of tumor cells; spindle 
cells and epithelioid cells. The most common tumor cell type is type B spindle cells, which 
are fusiform with a spindle shaped nucleus and a clearly defined nucleolus (Figure 3). Type A 
spindle cells have a less clearly defined or absent nucleolus, but these cells are now 
considered nevus cells. The epithelioid cells are round or polygonal and the large nucleus 
contains one or two prominent nucleoli (Figure 4).(McLean, Foster, Zimmerman, & Gamel, 
2018) The most common tumor type is the mixed cell type, as the tumor need to be 
composed of at least 90 % of spindle or epithelioid cell type to be classified as one or the 
other.("Histopathologic characteristics of uveal melanomas in eyes enucleated from the 
Collaborative Ocular Melanoma Study. COMS report no. 6," 1998; McLean et al., 2018) 







Figure 3. Spindle cell-type tumor. Laminin staining (left, ×20) and PAS staining (right, ×40). 
Picture from patient at St. Erik Eye Hospital. 
 
 
Figure 4. Epithelioid cell-type tumor. Laminin staining (left, ×40) and PAS staining (right, 
×40). Picture from patient at St. Erik Eye Hospital. 
 
2.1.2 Epidemiology 
Uveal melanoma comprise 85 % of all ocular melanomas, which in turn represents 5 % of all 
melanomas. (A. D. Singh, Bergman, & Seregard, 2005) The natural course including 
recurrences and metastases was first described in parallel by Scottish surgeon James Wardrop 
(1782-1869) and Scottish ophthalmologist-anatomist Allan Burns (1781-1813). (Kivela, 
2018)  
The age of diagnosis is in general just over 60 years old (Andreoli et al., 2015; 
Aronow, Topham, & Singh, 2018; Bergman et al., 2002) but around a decade younger for 
Hispanics and Asians.(Shields, Kaliki, Cohen, et al., 2015) Some studies show a slight 




2016) while others don’t.(Aronow et al., 2018; Shields, Kaliki, Cohen, et al., 2015) Uveal 
melanoma in children and adolescents is very uncommon.(Al-Jamal et al., 2016) .  
The incidence in Europe is increasing from south to north with an incidence of 
less than 2 per million in Italy and Spain, increasing to more than 8 per million in the Nordic 
countries.(Bergman et al., 2002; Virgili et al., 2007) (Krohn, Monge, Skorpen, Mork, & Dahl, 
2008) In the US, the general incidence has been estimated to 5.1-5.2(Aronow et al., 2018; 
Mahendraraj et al., 2016) with a small but significant increase of 0.5 % in whites.(Aronow et 
al., 2018) The incidence in Canada is 3.8 per million with a steady slow increase.(Ghazawi et 
al., 2019) Uveal melanoma is very uncommon in Hispanic, Asian and Black populations, 
representing only 2-5 percent of all affected individuals while Caucasians stand for the 
remaining 95-98 %.(Aronow et al., 2018; Mahendraraj et al., 2016; Phillpotts et al., 1995; 
Shields, Kaliki, Cohen, et al., 2015) High incidences of 9.5 and 8.0 per million have been 
reported in Ireland and Australia, respectively. (Baily et al., 2019) (Vajdic et al., 2003) A 
very low incidence of 1.9 per million has been reported from Japan.(Tomizuka, Namikawa, 
& Higashi, 2017) Generally, incidences increase with the latitude.(Yu, Hu, & McCormick, 
2006) 
 
2.1.3 Pathogenesis  
Risk factors for developing choroidal or ciliary body melanoma is having fair skin and light-
colored eyes. Having congenital ocular melanocytosis or melanocytoma has also been 
identified. Further, the BAP1-tumor disposition syndrome is a risk factor, (Walpole et al., 
2018) which is a cancer syndrome including mesothelioma, cutaneous melanoma, uveal 
melanoma and renal cell carcinoma. (Masoomian, Shields, & Shields, 2018) Whether there is 
a correlation between exposure to ultraviolet (UV) radiation and uveal melanoma is still not 
clearly understood, some studies show weak association and some studies show no 
association.(Mallet, Gendron, Drigeard Desgarnier, & Rochette, 2014; A. D. Singh, Rennie, 
Seregard, Giblin, & McKenzie, 2004) Very little UV radiation reaches the retina and 
underlying choroid after passing the cornea, lens and vitreous body in adults(Sliney, 2002) 
and uveal melanomas show low presence of mutations associated with UV damage.(Mallet et 
al., 2014) As the incidence of uveal melanoma and cancers in the periocular region remain 
stable, while cutaneous melanoma is steadily increasing in incidence, it has been suggested 
that UV exposure differs in the periocular region from the rest of the body.(Weis et al., 2019) 
However, as fair skin color with easy sunburn, as well as freckles and light eye color have 
been identified as risk factors for uveal melanoma in a large meta-analyses, the correlation to 
UV light is still under investigation. Cutaneous and iris nevi were also risk factors as well as 
welding and occupational cooking. In contrast, free time activities outside, work-related 
sunlight exposure, latitude of birth, and hair color had no significant correlation.(Nayman, 




Choroidal melanoma can arise de novo or from malignant transformation of 
choroidal nevi. The rate of choroidal nevi transforming in to melanomas has been estimated 
to less than 1 % in white Americans.(A. D. Singh, Kalyani, & Topham, 2005) Choroidal nevi 
are round to oval, flat and usually pigmented lesions and present in approximately 5 % of the 
adult population (>40 years, Americans).(Chien, Sioufi, Surakiatchanukul, Shields, & 
Shields, 2017) A commonly used mnemonic to remember risk factors for transformation of 
nevi into melanomas was created by professor Carol Shields (Wills Eye Hospital, 
Philadelphia, USA); “To find small ocular melanoma using helpful hints daily“, where T 
represents thickness exceeding 2 mm, F represents subretinal fluid, S represents symptoms of 
the vision being disturbed, O represents orange lipofuscin pigment, M represents margin with 
a shorter distance than 3 mm from the optic disc, U represents ultrasonographic hollowness, 
H represents absence of halo on ultrasound, and D represents absence of drusen.(Shields, 
Dalvin, et al., 2018; Shields, Furuta, Berman, et al., 2009) Melanomas less than 3 mm thick 
rarely spread, but share the same risk factors as larger melanomas.(Jouhi et al., 2019) 
Risk factors for developing iris melanoma from a nevus include being younger 
than 40 years old, episodes of hyphema (blood in the anterior chamber of the eye), location 
clockwise between 4 and 9, diffuse tumor involving the entire iris surface and feathery 
margins.(Shields, Kaliki, Hutchinson, et al., 2013) 
 Metastases spread hematogenously, with 90% spreading to the liver but also to 
the lungs (28-31%) and bone (18-23%). Brain metastases and spread to lymph nodes, 
subcutaneous tissue or the gastrointestinal tract is less common. More than half of the patients 
have only 1 organ involved, around 25 % 2 organs and very few 3 organs or more. (Diener-
West et al., 2004; Lorigan, Wallace, & Mavligit, 1991)  
 
2.1.4 Genetics 
In 2004 uveal melanoma was categorized in two different gene expression profiles (GEP) and 
a classifier for clinical use is available.(Onken, Worley, Ehlers, & Harbour, 2004; Onken, 
Worley, Tuscan, & Harbour, 2010) GEP1 is associated with a more favorable prognosis than 
GEP2.(Onken et al., 2004) Lately however four categories of uveal melanoma has been 
defined (A-D) where GEP1 are A and B tumors and GEP2 are C and D tumors, divided 
further after their chromosome 6 and 8 status and inflammatory phenotype.(Robertson et al., 
2017) (Jager, Brouwer, & Esmaeli, 2018)  
There are five different genes identified to contain mutations important for the 
prognosis of uveal melanoma; BAP1, EIF1AX, SF3B1, GNAQ and GNA11. The notion that 
there are consistent alterations in a few chromosomes is known from cytogenetic studies from 
over 30 years back.(Sisley et al., 1990; Sisley et al., 1997) Lack of the whole chromosome 3; 
monosomy 3, occurs in around half of patients with uveal melanoma and is the most 
significant chromosome abnormality with a connection to worse prognosis,(B. Damato et al., 




Amplification of the long arm of chromosome 8q (around 40 % of patients), or loss of 8p 
(around 25 %) is also associated with shorter survival,(van den Bosch et al., 2012) as well as 
loss of chromosome 6q which is seen in one quarter of patients. Gain of chromosome 6p is 
present in around 25 % and is on the contrary a positive alteration. Whether it depends on the 
aberration itself or the fact that gain of chromosome 6p is associated with a lack of 
monosomy 3, is yet not clear.(Nichols, Richmond, & Daniels, 2016) Mutation in the BAP1 
tumor suppressor gene is strongly associated with high risk of metastatic disease and tumor-
related death.(Decatur et al., 2016; Harbour et al., 2010; Jager et al., 2018) BAP1 is a tumor 
suppressor located at chromosome 3p21 and has been suggested as explanation to why 
monosomy 3 is associated with poorer prognosis.(Harbour & Chao, 2014; Robertson et al., 
2017) Mitogen-activated protein kinase (MAPK) is a pathway which in the end affects cell 
proliferation, differentiation and apoptosis. The vast majority of uveal melanoma have an 
activated MAPK pathway, which is seldom caused by a BRAF mutation but rather from 
mutations in the mutually exclusive driver mutations in the guanine nucleotide-binding 
protein GNAQ and GNA11.(Van Raamsdonk et al., 2009; Van Raamsdonk et al., 2010) 
GNAQ or GNA11 is present in 85 % of uveal melanomas, whereas BRAF mutations, which 
are quite common in cutaneous melanomas, are rare (Davies et al., 2002; Patel et al., 2011). It 
has also been shown that a majority of choroidal nevi carry a mutation in GNAQ or 
GNA11.(Vader et al., 2017) Mutations in EIF1AX and SF3B1 has been identified to be 
frequently present in uveal melanomas with disomy 3, which carry a positive 
prognosis.(Martin et al., 2013) 
 In contrary to most tumors in which the metastases carry similar mutations to 
the primary tumor,(Reiter et al., 2018; Vogelstein et al., 2013) uveal melanoma metastases 
have quite many mutational changes compared to the primary tumor.(Shain et al., 2019) 
  
2.1.5 Diagnosis 
The diagnosis of choroidal melanoma is established with fundus examination through slit 
lamp biomicroscopy and/or indirect ophthalmoscopy in conjunction with B-scan 
ultrasonography, which provides a better possibility than optical coherence tomography 
(OCT) to determine the shape of the tumor and also see acoustic hollowness and choroidal 
excavation.(Coleman et al., 2004) A-scan ultrasonography is also performed to evaluate 
internal reflectivity, being low in choroidal melanoma as opposed to choroidal hemangioma, 
which can have a similar shape but have high internal reflectivity. In case of intermediate 
internal reflectivity, choroidal metastasis should be suspected. These examinations are 
sufficient for diagnosis of choroidal melanoma and initiation of treatment, as the accuracy has 
been shown to be almost 100 %.("Accuracy of diagnosis of choroidal melanomas in the 
Collaborative Ocular Melanoma Study. COMS report no. 1," 1990; "Histopathologic 
characteristics of uveal melanomas in eyes enucleated from the Collaborative Ocular 




Transscleral or transvitreal biopsy is indicated when diagnostic uncertainty 
occurs, usually between amelanotic melanoma and metastatic adenocarcinoma, or other even 
less frequent tumors. To visualize iris and ciliary body tumors ultrasound biomicroscopy 




Figure 5. Iridociliary melanoma (middle) visualized by AS-OCT (left) versus UBM (right). 
Note how the margins are much more clearly visible in UBM. Reprinted with permission by 
Elsevier.(Bianciotto et al., 2011) 
 
Fluorescein and/or indocyanine green angiography are not needed for diagnosis but can be of 
value when there are differential diagnostic considerations from other choroidal 
tumors.(Shields, Shields, & De Potter, 1995) MRI can be valuable when extraocular tumor 
growth needs to be excluded.(Beenakker et al., 2016) Autofluorescence images show 
hyperfluorescence if there is presence of orange pigment in the melanoma, while benign nevi 
generally show hypo- or isofluorescence.(Shields, Bianciotto, Pirondini, et al., 2008; Shields, 
Pirondini, et al., 2008)  
Specific biomarkers for early detection of uveal melanoma and also detection of 
metastatic disease is a hot research field, but no markers are yet clinically in use.(Bande 
Rodriguez et al., 2020; Triozzi & Singh, 2012) 
 
2.1.6 Prognosis 
While only 2 % of patients have metastatic disease at presentation, unfortunately 15 % and 25 
% of the patients suffer from metastatic spread after 5 and 10 years respectively, when 
considering all locations.(Shields, Furuta, Thangappan, et al., 2009)  
Ciliary body melanomas and diffuse melanomas are associated with a higher 
risk of metastatic disease compared to choroidal melanomas, while iris melanomas have a 
lower risk, which can be attributed to the hidden or clearly visible location of these respective 
lesions which affects the time to discovery.(Kaliki, Shields, & Shields, 2015; Nichols et al., 




melanomas metastasize in 4 % and 7 %, choroidal melanomas in 15 % and 25 %  and ciliary 
body melanomas in 19 % and 33 % respectively.(Shields, Furuta, Thangappan, et al., 2009)  
Every mm increase in thickness and diameter is associated with higher risk of 
tumor spread (Diener-West et al., 2004; Shields, Furuta, Thangappan, et al., 2009; Shields, 
Sioufi, et al., 2018). Small melanomas up to 3 mm thick have a 5-, 10- and 20-year risk of 6 
%, 10-12 % and 20 % for metastatic disease, medium sized tumors 3 to 8 mm have a 14 %, 
26 % and 37 % risk respectively, and large tumors more than 8 mm thick a considerably 
higher risk of 35-38 %, 49 % and 67 %.(Shields, Furuta, Thangappan, et al., 2009)   
Higher age at diagnosis is also a risk factor for metastatic disease.(Shields, 
Kaliki, Furuta, Mashayekhi, & Shields, 2012) Tumors in non-Caucasian patients are 
generally thicker, more hemorrhagic and more peripheral at diagnosis, but the risk of 
metastatic spread and overall survival does not differ from Caucasians.(Andreoli et al., 2015; 
Shields, Kaliki, Cohen, et al., 2015) Patients with ocular or oculodermal melanocytosis, 
which have an increased risk of uveal melanoma, have a doubled risk for metastatic spread 
compared to uveal melanoma patients without melanocytosis.(Shields, Kaliki, Livesey, et al., 
2013) 
In a study of pediatric uveal melanoma, that our group contributed to as part of 
the European Ophthalmic Oncology Group, uveal melanoma has been described in patients 
as young as less than 3 years old. In young patients with uveal melanoma, the prognosis 
seems to be more favorable for children younger than 10 years old, with no metastases found 
after 10 years follow up. In children 10 to 17 years, the proportion of patients suffering from 
metastatic disease was 9 %, and in the group of young adults 18 to 25 years old it was 17 %. 
In patients older than 10 years old there was also a worse prognosis for female patients, 
which was not observed in the group younger than 10 years old.(Al-Jamal et al., 2016)   
If the melanoma consists almost exclusively of spindle cells the risk of 
metastatic disease is lower than if the melanoma is mixed with epithelioid cells. The higher 
the percentage of epithelioid cells and the bigger they are, the higher the risk of tumor 
spread.(B. Damato et al., 2007; McLean et al., 2018) 
Local tumor recurrence after treatment is associated with a higher risk of 
metastatic spread, demonstrated in a few small studies(Caujolle et al., 2013; Gragoudas, 
Lane, Munzenrider, Egan, & Li, 2002; Jampol et al., 2002; Vrabec et al., 1991) but later 
confirmed by a large multicenter study.(Ophthalmic Oncology Task, 2016) 
After discovery of a metastasis, the median survival time is 4-15 months in 
different reports, with a widely ranging survival rate of 15-50 % and 8-30 % after 1 and 2 
years, respectively.(Augsburger, Correa, & Shaikh, 2009; Collaborative Ocular Melanoma 
Study, 2006; Diener-West et al., 2004; Khoja et al., 2019; Kuk et al., 2016; Rietschel et al., 
2005) Rietschel et al noted that surviving patients after 2 years also seem to have a less steep 




reported a longer survival time in females (Rietschel et al., 2005) with metastatic uveal 
melanoma, which was supported by a meta-analysis by Khoja et al.(Khoja et al., 2019) 
In Sweden the 5 year relative survival after ruthenium-106 brachytherapy is reported to 
95 %.(Bergman, Nilsson, Lundell, Lundell, & Seregard, 2005)  Overall, the 5-year relative 
survival of uveal melanoma of around 80 % remains unchanged in most countries.(Aronow et 







The first eye-sparing treatments were carried out by ophthalmologist Richard Deutschmann 
in Hamburg, Germany, 1915 by implanting capsules with mesothorium (radium-228) in 
fractioned doses. Later on in London, 1929, R Foster Moore implanted radon-222 seeds 
directly in a choroidal sarcoma and thereby managed to treat the tumor while still preserving 
vision.(Moore, 1930) Also in London, Hyla Bristow Stallard started treating 
rhabdomyosarcoma with seeds of cobalt-60 in the 1940s and improved his technique by using 
first wax and then later silver or gold shielded cobalt-60 placed on the episcleral surface. 
(Stallard, 1948, 1966)  In the 1960s Peter Lommatzsch started using ruthenium-106 
successfully in Leipzig, Germany. (Lommatzsch, 1986) By the work of Samuel Packer and 
Marvin Rotman in New York, iodine-125 replaced cobalt-60 resulting in less damage to 
healthy tumor-surrounding tissue, a consequence from iodine-125s faster dose fall off. 
(Packer & Rotman, 1980) Brachytherapy with radioactive nuclides has over the years become 
the predominantly used treatment for small to medium-sized tumors.(Aronow et al., 2018)  
In 1984, 43 clinical centers in North America formed the Collaborative Ocular 
Melanoma Study Group (COMS) which performed the first randomized controlled studies on 
ocular melanoma treatment.(Arun D. Singh & Kivelä) In one of the studies, patients with 
medium sized tumors were enrolled between 1987 and 1998 and randomized to either iodine-
125 brachytherapy or primary enucleation.(Jampol et al., 2002) Iodine-125 was chosen over 
cobalt-60 as it had comparable and sufficient tissue penetration up to 15 mm thickness, 
however requiring only 0.5 mm of a gold shield to shield off the radiation to less than 0.1 %, 
while 60-cobalt had 50 % radiation left with a shield of 12 mm lead. Iodine-125 is a photon 
emitter, its half-life extending to 60 days. It decays through electron capture to an excited 
state of tellurium-125 which, while emitting a 35.5 keV gamma photon, decays to its ground 
state.(Khan & Gibbons, 2014; Marwaha, Macklis, Singh, & Wilkinson, 2013) The 
prescription dose to the tumor apex was set to 100 Gy, (Earle, Kline, & Robertson, 1987) 
revised to 85 Gy by the Radiation Therapy Committee of the American Association of 
Physicists in Medicine in 1995(Nath et al., 1995) The American Brachytherapy Society has 
later on updated the recommendations in 2003 stating a minimum dose rate of 0.60 Gy/h and 
a dose still of 85 Gy for iodine-125, based on the COMS standard. A further update in 2014 
supplied a dose recommendation range of 70-100 Gy. No specific dosimetric 
recommendations are available for other radionuclides. (American Brachytherapy Society - 
Ophthalmic Oncology Task Force. Electronic address & Committee, 2014) 
In 2001 results were published, which showed no difference in survival when 
comparing treatment of medium-sized melanomas with iodine-125 to primary 
enucleation.(Diener-West et al., 2001b) This put an end to concerns both that enucleation 
caused seeding of melanoma cells and an increasing risk of metastatic disease, as well as 
concerns that brachytherapy would not be as effective as primary enucleation.(A. D. Singh, 




follow up of 12 years in 2006.("The coms randomized trial of iodine 125 brachytherapy for 
choroidal melanoma: V. twelve-year mortality rates and prognostic factors: coms report no. 
28," 2006) Local treatment failure was 10 % after 5 years in the brachytherapy group and 15 
% had secondary enucleation.(Jampol et al., 2002) Patients included in the report did not have 
melanomas located contiguously with the optic disc or melanomas extending more than a 90 
degree angle of the optic disc if they were located within 2 mm.(Diener-West et al., 2001a) 
Reports on brachytherapy treatment of juxtapapillary choroidal melanomas both with iodine-
125 and ruthenium-106 have however showed comforting results of similar recurrence rates 
as with treatment of melanomas further from the optic disc.(Lommatzsch & Lommatzsch, 
1991; Sagoo et al., 2011) 
While iodine-125 is the most commonly used nuclide overall and foremost in 
the US, ruthenium-106 is widely used in Europe, (Pe'er, 2012; Stefan Seregard & Damato, 
2014) Both radionuclides offers a highly safe option for plaque surgeons, albeit surgery time 
should be kept to a minimum and the number of procedures should not exceed 200 per 
year.(Laube, Fluhs, Kessler, & Bornfeld, 2000) 
Ruthenium-106 is a β ray electron emitter with a half-life of 373 days (Pe'er, 
2012). It decays to rhodium-106 which has a half-time as short as 30 seconds, thus almost 
immediately decaying further to its ground state of palladium-106, while emitting beta 









Figure 6. A) Approximate dose fall-off curves for ruthenium-106 (106Ru, blue) and iodine-
125 (125I, yellow) plaques when 85 Gy is prescribed at the apex +1 mm of 5 mm thick (solid 
lines) and 7 mm thick (dotted lines) tumors. For every millimeter of penetration into the 
tissue, the dose fall-off for the β-emitting 106Ru is approximately threefold faster than for the 
γ-emitting 125I. This implicates that scleral doses have to be significantly higher with 106Ru 
than 125I for equivalent doses at the tumor apex. B) Comparison of theoretical two- 
dimensional dose distributions of a 125I plaque (left) and a 106Ru plaque (right), both 
planned with a dose of 85 Gy to the apex of a thin tumor. 125I delivers higher doses to tissues 
beyond the tumor, and to tissues lateral to the plaque margin. B reprinted with permission 
from Eckert & Ziegler BEBIG, Berlin, Germany.(Fili et al., 2020) 
 
 Other nuclides that have been used for plaque brachytherapy include irridium-
192 and cobalt-60, not preferred as both are high-energy gamma emitters that deliver large 
radiation doses to healthy tumor-surrounding tissue and also present a risk of radiation 
exposure to caregivers. Palladium-103 has a faster dose fall of than iodine-125, but not as fast 
as ruthenium-106, and is used in some centers.(Finger, Chin, Duvall, & Palladium-103 for 
Choroidal Melanoma Study, 2009; Nag et al., 2003) In the most recent recommendations 
from the American Brachytherapy Society (ABS) – OOTF, the radionuclides used were 
summarized as iodine-125 and palladium-103 in North America, iodine-125 or ruthenium-
106 in Europe, only ruthenium-106 in Japan, and in Russia ruthenium-106 or strontium-
90.(American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic address 




2.2.2 Ophthalmic applicators 
Ophthalmic applicators used in Sweden are produced in Germany by Eckert & Ziegler 
BEBIG, Berlin, Germany. They manufacture the COMS gold coated iodine-125 plaques as 
well as silver coated ruthenium-106 plaques, being the sole producer globally for the latter. 
They are spherically shaped and plaques up to 25 mm in diameter are available, but most 
centers use plaques with diameters of up to 20 mm. Since a safety margin of 2 mm is 
recommended around the tumor, the maximum tumor diameter treatable with plaque 
brachytherapy is 16 mm in most centers. (American Brachytherapy Society - Ophthalmic 
Oncology Task Force. Electronic address & Committee, 2014; Nag et al., 2003) In posterior 
tumors the safety margin might be omitted in some cases, in order to save the macula and 
optic disc from radiation, as long as the dose to the scleral surface is at least 300 Gy.(B. 
Damato, Patel, Campbell, Mayles, & Errington, 2005) 
Iodine-125 plaques are loaded with iodine seeds for each treatment, the number 
of seeds needed calculated based on present radioactivity in the seeds and tumor size. The 
seeds are encapsulated in 0.05 mm titanium tubes, which are welded at each end creating an 
uneven dose distribution with the lowest dose at the ends. Up to 24 seeds can fit into each 
plaque.  
 





 In ruthenium-106 plaques, on the concave side of the plaque there is a thin film 
of ruthenium-106 covered by a 0.1 mm silver foil that works as a radiation window. The back 
of the plaque has a 0.7 mm thick silver foil and functions as a radiation shield, which absorbs 
about 95 % of the beta radiation. According to Eckert & Ziegler, each plaque is calibrated 
according to a certified reference dose rate from the National Institute of Standards and 
Technology, USA (NIST). The reference point is at the plaque axis 2 mm from the surface 
and the absorbed dose rate to water is 4.8 Gy/h, which equals approximately 7.2 Gy/h at the 
scleral surface. The dose absorbed in tissue decreases to one tenth of its initial value after 7 




Figure 8. Ruthenium-106 plaques. Reprinted with permission from Eckert & Ziegler BEBIG 
GmbH. 
2.2.3 Brachytherapy treatment procedure 
Treatment is performed under general anesthesia. The conjunctiva is opened and a light 
source is put to the pupil, locating the tumor which appears as a dark shadow in the sclera. 
The plaque is placed over the tumor base with a safety margin of 2-3 mm. If necessary, 




plaque. In the event of a tumor located close to the optic disc, adjunctive treatment with 
transpupillary thermotherapy (TTT) is sometimes administered. After planned treatment 
duration is reached, the plaque is removed, muscles are reinserted and the conjunctiva sewn 
back in place.  
2.2.4 Ophthalmic brachytherapy in Sweden 
In Sweden, brachytherapy treatment with ruthenium-106 started up in 1979 and 20 years later 
iodine-125 became available as treatment of choice for tumors more than 6-7 mm thick. 
Large tumors more than 10 mm thick are still treated with primary enucleation due to 
concerns for insufficient radiation doses. Similarly, lesions located adjacent to the optic nerve 
may be treated with primary enucleation regardless of tumor size, due to surgical 
inaccessibility. 
A standard dose of 100 Gy to the tumor apex was prescribed when ruthenium-106 
was introduced in 1979, and a maximum dose of 1000 Gy was set to the scleral surface. In 
1999 the maximum scleral dose was increased to 1500 Gy and iodine-125 was introduced 
with an estimated treatment dose of 85 Gy to the tumor apex. During the 20 years when only 
ruthenium-106 was available, some thicker tumors than 7 mm were treated, when eye 
preserving treatment was highly desirable.  
2.2.5 Radiation biology 
Brachytherapy constitutes implantation of radioactive sources inside or next to the tumor, 
brachy meaning short distance in Greek. (Hall & Giaccia, 2011) A nuclide is defined by an 
atoms combination of protons and neutrons, in conjunction with its energy state. An isotope 
is defined by one elements differing number of neutrons. The ionizing radiation which is 
emitted when subatomic bonds break and radionuclides and radioisotopes decay into more 
stable forms, can create ions by displacing electrons from atoms or molecules. The tissue that 
absorbs ionizing radiation forms free radicals and ions when chemical bonds break between 
molecules. These oxidize DNA and other contents in the cells. The cell loses its capacity to 
reproduce and, if repair mechanisms are insufficient, undergo apoptosis. The SI unit for 
absorbed radiation is Gray. One Gray equals 1 Joule of energy absorbed by 1 kg tissue.(Khan 
& Gibbons, 2014; A. D. Singh, Pelayes, Seregard, Macklis, & Bandello, 2013) 
2.2.6 Radiation effects on ocular tissue 
After brachytherapy of a choroidal melanoma, radiation retinopathy occurs in over 60 % of 
patients. (S. Seregard, Pelayes, & Singh, 2013) Dose rates more than 2.6 Gy/h to the tumor 
base as well as if the margin of the melanoma base is under 4 mm from the fovea, are both 
risk factors associated with a higher risk of this complication. (Gunduz et al., 1999b) 
Exudative retinal detachment due to increased vascular permeability can be seen directly after 
radiation, sometimes resolving, but chronic retinal detachment is not uncommon. If the 
patient suffers from diabetes, there is a higher risk of radiation induced proliferative 




exudative retinal detachment is referred to as a type of toxic tumor syndrome.(Groenewald, 
Konstantinidis, & Damato, 2013; Gunduz et al., 1999b) Radiation induced macular edema is 
treated with intravitreal corticosteroids and/or anti-VEGF, both treatments leading to 
improvement. However, spontaneous improvement may occur why more studies on the effect 
is needed.(Giuliari, Sadaka, Hinkle, & Simpson, 2011; Groenewald et al., 2013) Edema is the 
earliest sign of radiation maculopathy, a complication which not surprisingly corresponds to 
the distance between the fovea and the tumor margin as well as radiation doses exceeding 50 
Gy.(Gunduz et al., 1999b; Pagliara et al., 2018) 
A dose of more than 50 Gy received by the optic nerve constitutes a risk for 
optic neuropathy. Treatment with intravitreal steroids has little effect on vision improvement, 
and systemic corticosteroids have no effect. Hyperbaric oxygen therapy may have effect if 
administered early.(Groenewald et al., 2013) Developing cataract is a risk if the irradiation to 
the lens is more than 10 Gy. Treatment is with standard cataract surgery with good 
results.(Wachtlin et al., 2000)The reported incidence of radiation induced cataract, 
maculopathy and optic neuropathy varies widely from just a few percent to more than 80 %, 
60 % and 30 % respectively. (Naseripour et al., 2016; Takiar et al., 2015; Wen, Oliver, & 
McCannel, 2009) In comparing 106-ruthenium with 125-iodine Wilkinson et al found an 18 
% lower radiation dose to the macula, 53 % lower radiation dose to the optic disc, and as low 
as 89 % lower radiation dose to the lens for tumors < 5 mm thick.(Wilkinson, Kolar, Fleming, 
& Singh, 2008) Scleral necrosis is a rare complication seen in less than 10 % of treated 
patients at 10 years after brachytherapy. There is an increased risk for thicker tumors, if there 
is ciliary body involvement and if there is higher intraocular pressure. (Gunduz et al., 1999a; 
Radin et al., 2008) 
2.2.7 Radiation effects on uveal melanoma 
Irradiated tumor cells undergo necrosis or apoptosis, and tumor blood vessels loose 
endothelial cells which leads to vascular occlusion followed by fibrosis. Less subretinal fluid 
and increased pigmentation as well as increased internal reflectivity on ultrasound 
examination are clinical findings after treatment. (Maheshwari & Finger, 2018; A. D. Singh, 
Rennie, Kivela, et al., 2004) The rate of tumor regression depends on which type of 
radiotherapy that has been used (ruthenium faster than iodine) and tumor thickness (thicker 
tumors regress faster).(Rashid, Heikkonen, Singh, & Kivela, 2018) These findings support 
the notion that in ocular brachytherapy, fast regression is not only due to shorter doubling 
times in aggressive tumors, but is also related to the very high radiation doses administered to 
the tumor base, causing immediate cell disruption, vessel obliteration and tumor 
infarction.(B. Damato, 2018) A rapid regression of tumor size after radiation correlates to 
worse prognosis according to some(Augsburger, Gamel, Shields, Markoe, & Brady, 1987; 
Kaiserman et al., 2004), but not all authors,(Pepin et al., 2019) and some have found that 
rapid regression is associated with earlier metastases and slow regression with late metastases 
(after 2 years).(Glynn, Seddon, Gragoudas, Egan, & Hart, 1989) A great number of 




Damato, 2018), as well as a dark pigmented tumor.(Rashid et al., 2018) Consideration must 
also be taken in regression pattern, as oval to dome shaped or mushroom shaped tumors seem 
to regress more in area than thickness.(Rashid, Heikkonen, & Kivela, 2015)  
Since monosomy 3 is associated with worse prognosis, fast regression rate and 
the presence of monosomy 3 have been investigated, not showing such correlation in some 
studies (Chiam et al., 2014; Gupta et al., 2016; Salvi et al., 2017) but indeed in 
others.(Shields, Bianciotto, Rudich, et al., 2008)  GEP1 has been linked to faster regression 
than GEP2 the first 6 months after iodine-125 brachytherapy.(Mruthyunjaya, Seider, Stinnett, 
Schefler, & Ocular Oncology Study, 2017) As irradiated tumors show a higher frequency as 
well as a higher complexity of chromosomal aberrations than untreated tumors,(Dogrusoz et 
al., 2015) questions have been raised whether the treatment itself allows or induces metastatic 
progress when local failure occurs.(B. Damato, 2018) 
 
 
Figure 9. Choroidal melanoma treated with brachytherapy. A) Successfully treated area with 
a yellowish atrophic appearance. B) Large area of tumor relapse. C) Asteroid hyalosis in the 
vitreous body, incidental finding not related to uveal melanoma.(Burris et al., 2017) Picture 







2.2.8 Other treatments 
As mentioned earlier, large tumors 10 mm thick or more are still primarily treated with 
enucleation. If there is major extraocular growth, exenteration is the only option, where all 
tissue in the orbital cavity is removed.  
Local resection of medium sized and large tumors is performed by internal 
evacuation or external lamellar sclerouvectomy in some ophthalmic oncology centers. 
Various results have been described, some report a high local recurrence rate of 30 % (Hong, 
Wei, Hua, Xu, & Shao, 2014)  after 5 years, while others report 10 % in the presence of 
neoadjuvant proton beam therapy in addition to local resection. The rate of complications 
requiring additional vitreoretinal surgery in the latter study was however very high (70 
%).(Willerding et al., 2016) In a comparison between neoadjuvant proton beam therapy and 
adjuvant ruthenium-106 brachytherapy together with local resection for large tumors there 
was an eight fold higher risk of local recurrence with brachytherapy, but no difference in risk 
of enucleation or metastatic spread.(Boker et al., 2018) Concerns about these techniques are 
that external approach requires hypotensive anesthesia and there is also worries about tumor 
seeding. Further analysis on these risks and also the advantages to brachytherapy is 
needed.(B. E. Damato, 2012) 
Charged particle therapy is an external radiation technique using protons, 
helium or carbon. Protons are most commonly used and they produce low irradiation when 
traveling through a mass until they stop, where they deliver the maximum of their energy, 
called the Bragg peak. Treatment for choroidal melanoma is generally 56-60 Gy delivered to 
the prescription point in 4 daily fractions, but doses up to 70 Gy in 5 daily fractions are also 
within treatment standards.(Hrbacek et al., 2016) The anterior segment complications and 
secondary enucleation rates have been reported to be of higher frequency than for iodine-125 
treatment,(American Brachytherapy Society - Ophthalmic Oncology Task Force. Electronic 
address & Committee, 2014) but other studies including a large meta-analysis covering over 
8000 patients showed no survival benefit or difference in eye retention rate compared to 
brachytherapy.(Abrams, Gagne, Melhus, & Mignano, 2016; Wang et al., 2013) The rate of 
local recurrence after charged particle therapy is however reported to be lower than after 
plaque brachytherapy.(B. Damato, Kacperek, Chopra, Campbell, & Errington, 2005; 
Desjardins et al., 2012; Wang et al., 2013) 
Other treatments like stereotactic photon beam therapy and endoresection are less 
common but also provide a high degree of local control. (Dunavoelgyi et al., 
2011) (Konstantinidis, Groenewald, Coupland, & Damato, 2014) 
 
2.2.9 Follow up and screening for metastases 
In Sweden ocular examination is performed 1,3 and 6 months after brachytherapy or 




occur many years after treatment.(Ophthalmic Oncology Task, 2016) Screening for 
metastasis is done by liver ultrasound or CT semiannually for 5 years. Ultrasound offers a 
high sensitivity and specificity for suspected metastatic lesions and excellent specificity is 
achieved with confirmatory CT scan.(Choudhary, Gupta, Bena, Emch, & Singh, 2016) Liver 
function blood tests are not used in Sweden, they are not effective for early detection of 
metastases but have a high negative predictive value (Mouriaux, Diorio, Bergeron, Berchi, & 
Rousseau, 2012)  and high LDH was associated with shorter survival in a Dutch nationwide 
cohort of advanced disease.(Jochems et al., 2019) Other blood biomarkers for detection of 
metastases have not been proven reliable enough for clinical use.(Bande Rodriguez et al., 
2020; Triozzi & Singh, 2011, 2012) 
 
2.2.10 Adjuvant treatment and treatment of metastatic disease 
TTT is an accepted adjuvant treatment for juxtapapillary tumors but is not advised as primary 
treatment even for small melanomas. (Harbour, Meredith, Thompson, & Gordon, 2003; 
Mashayekhi et al., 2015; Win, Robertson, Buettner, McCannel, & Bennett, 2006) 
Pre-enucleation radiation is seldom used as it has not shown any survival 
benefits.(Hawkins & Collaborative Ocular Melanoma Study, 2004) However, post 
exenteration or post enucleation of a tumor with some extrascleral growth is occasionally 
treated with external beam radiation therapy (EBRT, 50 Gy in 180-200 cGy fractions). To 
avoid radiation damage to eyelids, intraorbital brachytherapy is also an option.(Finger, 2009) 
Local resection is sometimes conducted with preoperative proton beam radiation or plaque 
radiation after the resection as described earlier.(Boker et al., 2018)  
Adjuvant treatment has not been proven effective and efforts using treatments 
for cutaneous melanoma for metastatic uveal melanoma has shown poor results, including 
antibodies inhibiting the programmed death receptor 1 (PD-1).(Algazi et al., 2016; Carvajal et 
al., 2017; Triozzi & Singh, 2014) Liver screening has been questioned since no effective 
treatment is available. However, since high diagnostic accuracy can be achieved by non-
invasive methods, the benefits are clear. By early detection of metastases, the patient may be 
offered the opportunity to make life altering decisions about palliative treatment. Early 
detection also increases the likelihood that a patient can be included in a clinical trial. 
(Choudhary et al., 2016) 
Tebentafusp is a new form of immunotherapy based on the monoclonal T cell 
receptor against cancer (ImmTAC) platform. It has an immune mobilizing function and 
targets cells that express HLA A0201 which has complexed with the peptide gp100. In 
melanoma Gp100 is expressed strongly, while it has only a weak expression in melanocytes, 
and in other tissue there is a minimal expression. Results are promising and further trials are 




Local treatment of liver metastases includes metastasectomy, local 
chemotherapy by arterial liver infusion and liver embolization, none of which has been 




























3 RESEARCH AIMS 
In paper I we studied whether dose rate applied to the scleral surface or tumor apex was 
associated with the risk of secondary enucleation in brachytherapy of uveal melanoma with 
ruthenium-106.  
In paper II we compared ruthenium-106 and iodine-125 regarding treatment outcome and 
survival in treatment of uveal melanomas 5.5 mm or thicker.  
In paper III we investigated gender differences in long-term survival after brachytherapy of 
uveal melanoma with ruthenium-106 and iodine-125.  
In paper IV we evaluated the effect of dose and dose rate on disease-specific mortality after 






















4 MATERIALS AND METHODS 
4.1 PATIENTS AND METHODS 
In paper I the computerized Medlog V.2012-8 (Information Analysis, Crystal Bay, Nevada, 
USA) registry of all patients in Sweden treated with brachytherapy for uveal melanoma was 
searched. Later on, in paper II-IV, the Medlog registry had been replaced by the 
Brachytherapy of Uveal Melanoma registry (BRUM) (Registry Center South, EyeNet 
Sweden), from were all patient data was retrieved.  
Date and cause of death was retrieved from the National Mortality Registry. 
This registry contains data on cause of death of all diseased persons in Sweden. As 
misclassifications of the actual cause of death is frequent between cutaneous and uveal 
melanoma,(Bergman et al., 2003) we cross-checked the National Mortality Registry’s data 
with our own clinical records of patients’ metastases. If a patient had metastasized uveal 
melanoma and later died from metastasized melanoma without any records of diagnosed or 
treated cutaneous melanoma, we considered the cause of death set as cutaneous melanoma as 
misclassified. 
In paper I, 962 patients treated with ruthenium-106 from 1 November 1979 to 
31 December 2012 was included. In total eight groups - two sets of approximate quartiles 
based on dose rates at the tumor apex and the scleral surface, respectively, were created. Data 
regarding age at diagnosis, gender, eye laterality, tumor thickness, tumor diameter, AJCC T-
category(Edge et al., 2010), tumor distance to the optic disc, tumor distance to the macula, 
dose rate to the scleral surface, dose rate to the tumor apex, enucleation after brachytherapy 
and reason for enucleation was analyzed. 
In paper II, 1493 patients treated with either ruthenium-106 or iodine-125 
brachytherapy from 1 November 1979 to 31 December 2015 were included and data 
regarding tumor thickness, tumor diameter, brachytherapy nuclide (ruthenium-106 or iodine-
125), retreatment, rates of TTT, enucleation after brachytherapy and survival was analyzed. 
Matched subgroups were created in consideration of recommendations for 1:1 nearest 
neighbor matching. Values with the highest impact on the means of age at diagnosis, gender, 
pretreatment visual acuity, tumor thickness, tumor diameter, AJCC T-category(Kivelä et al., 
2017) and follow up years were excluded until all differences became non-significant in 
Mann-Whitney U tests(Stuart, 2010). Two pairs of matched subgroups were made, one pair 
of 55+55 patients with tumors 5.5-7.4 mm thick and one pair of 45+45 patients with tumors 
≥7.5 mm thick, treated with ruthenium-106 and iodine-125 respectively. 
In paper III, 1541 patients treated with either ruthenium-106 or iodine-125 
brachytherapy for uveal melanoma from 1 November 1979 to 20 November 2017 were 
included and data regarding gender, age at diagnosis, pretreatment best corrected visual 
acuity, symptom duration before presentation, type of symptoms, tumor origin, tumor 




(ruthenium-106 or iodine-125), prescribed radiation dose, treatment duration, TTT before or 
after brachytherapy, enucleation after brachytherapy, date of metastasis and follow up years 
was analyzed. 
In paper IV, 1238 patients treated with brachytherapy for uveal melanoma from 
25 April 1996 to 16 March 2016 were included and data regarding age at diagnosis, gender, 
pretreatment best corrected visual acuity, symptom duration before presentation, type of 
symptoms, tumor thickness and diameter, AJCC T category(Kivelä et al., 2017), 
brachytherapy nuclide (ruthenium-106 or iodine-125), prescribed radiation dose, planned 
treatment duration, actual treatment duration, TTT before brachytherapy, date of death 
(melanoma-related, from other causes or unknown cause) and follow up years was analyzed. 
For all patients in paper I-IV, tumor thicknesses and diameters were measured 
pre-operatively by standardized A and B-scan ultrasonography. From 1979-1999 ruthenium-
106 was the only nuclide available. Maximum dose at the tumor apex was 100 Gy and to the 
scleral surface 1000 Gy. In 1999, iodine-125 was introduced as the treatment standard for 
thicker tumors more than 6-7 mm, with a maximum apex dose of 100 Gy which was lowered 
to 80 Gy in 2003 due to concern for surrounding tissue. Also, in 1999, the maximum dose to 
the scleral surface was increased to 1500 Gy.  
Ruthenium-106 plaques were of the CCA, CCB, CCX, CCZ, COB, CIA or CIB 
types (Eckert & Ziegler BEBIG, Berlin, Germany) with diameters up to 20 mm. Iodine-125 
plaques were custom made by a goldsmith in 18 carat gold, with 20 iodine-seeds (Eckert & 
Ziegler) glued to the concave surface. Radioactivity data for each plaque were independently 
verified by medical physicists at the Karolinska University Hospital, Solna, Sweden. 
Dosimetry was performed by using a p-type silicon semiconductor detector (Scanditronix, 
Sweden), estimating dose rate at different depths from the applicators convex surface with an 
estimated accuracy of ±4.5 %.(Lax, 1991) Silicon diodes have been used for dosimetric 
calculations of high-energy photon and electron beam radiation since the 60’s.(Rikner & 
Grusell, 1987)  Based on tumor size and the current radiation activity in the specific plaque, 
the exact individual treatment time for each patient was calculated by the medical physicists. 
Surgery was performed under general anesthesia. The tumor was located by 
transillumination, followed by plaque positioning with a minimum 2 mm margin around the 
melanoma. Tumors close to the fovea had eccentric plaque fixation and adjunctive laser 
therapy to the compromised tumor margin. Juxtapapillary melanomas were either treated with 
a notched plaque or standard plaque combined with adjunctive laser therapy. Some patients 
received pre-, peri-, or postoperative adjunctive argon laser photocoagulation or TTT. Follow 
up was scheduled at 1, 3, 6 and 12 months after treatment, and then annually for the rest of 
the patient’s life. Screening for liver metastases by ultrasonography or CT was performed 
semiannually for 5 years after diagnosis. After a few years, patients not from the Stockholm 
region were referred back to their home clinics. In case of tumor relapse, the patient was 
however referred back to our clinic as we are the sole treating clinic in the country. In case of 




histopathological analysis. Therefore, all data on relapse and enucleation are accurate. Date of 
last follow up might be lost for some patients, but most clinics in the country have a well-
established routine of sending copies of clinical records to our clinic for registration in the 
BRUM registry. 
All studies received approval from the Central Ethical Review Board, Stockholm, 
Sweden. 
 
4.2 STATISTICAL ANALYSIS 
Paper I: Statistical analysis was performed using Statistica V.12 software (Statsoft 
Scandinavia AB, Uppsala, Sweden). Level of statistical significance was set to p <0.05. 
Frequency distributions were studied by the median value and interquartile range as 
frequencies were not normally distributed. To evaluate differences between baseline 
characteristics in the groups, independent t test and one-way analysis of variance (ANOVA) 
were performed for continuous variables and for categorical variables the Pearson ꭓ2 test was 
used. Kaplan Meier survival curves were generated for each dose rate quartile and compared 
with the log rank (Mantel-Cox) test for secondary enucleation analysis. Univariate and 
multivariate analyses using Cox regression modelling was also performed. Data was 
consistently treated linearly in the Cox regression analyses.  
Paper II: Statistical analysis was performed using SPSS statistics V.25 (IBM, 
Armonk, New York, USA). In power calculations we studied the largest similar cohort 
published to date, in which the relative risk for tumor recurrence and enucleation after 
ruthenium-106 versus iodine-125 brachytherapy was 13.75 and 3.12 respectively.(Shields et 
al., 2002) To detect the smallest of these differences (risk for enucleation) with 80 % power 
at a significance level of 0.05, the sample size for each arm was estimated to 9 patients. 
Reversely, in our sample size we were able to detect differences of down to approximately 8 
% with 80 % power and 9 % with 90 % power. The Mann-Whitney U test was used for tests 
of the null hypothesis in non-parametrically distributed group level data. The Pearson ꭓ2 test 
was used for comparisons of proportions in two-by-two tables. For analyses of hazard for 
post brachytherapy enucleations, repeated brachytherapy and melanoma-related mortality, 
multivariate Cox regressions with tumor thickness and diameter as covariates were used. 
Kaplan-Meier survival curves were computed for matched subgroups and the log-rank 
(Mantel-Cox) test of equality of survival distributions was applied for analyses of disease-
specific survival and overall survival.  
Paper III: Statistical analysis was performed using SPSS statistics V.25 (IBM, 
Armonk, New York, USA). In power calculations for 90 % power, the sample size for each 
arm was estimated to at least 541 patients at a significance level of 0.05 and the smallest 
detectable difference between the groups of 10 %. Reversely, in our sample size of 775 men 
and 766 women, we would be able to detect differences of down to 8-9 % with 90 % 




of the null hypothesis in non-parametrically distributed group level data. The Pearson ꭓ2 test 
was used for comparisons of proportions in two-by-two tables. Bi- and multivariate Cox 
regression analysis with tumor thickness and diameter were used for analyses of hazard for 
post-brachytherapy enucleations, repeated brachytherapy and melanoma-related mortality. To 
test weather our survival data met the proportional hazard assumption, we built a Cox 
regression model with a time-dependent versus a time-independent treatment variable (man 
or woman).  Kaplan-Meier curves for disease-specific and overall survival were computed 
and the log rank (Mantel-Cox) test of equality of survival distributions was applied. 
Equivalence between men and women was tested as the relative risk for melanoma-related 
death with modified two-sided 95 % CIs as for binary endpoints.(Tunes da Silva et al., 2009) 
Paper II-IV: Visual acuity was measured on a decimal scale chart at a distance 
of 5 m (Monoyer Granström) ranging from 1.0 (corresponding to 20/20) to 0. Modified from 
standards in the Swedish National Quality Registry for Cataracts, counting fingers at a 
distance of 4 m was recorded as 0.08, hand movements as 0.04, perception and localization of 
light as 0.01 and amaurosis as 0. Average visual acuities were calculated on -1 LogMar 
converted values, and then converted back to the decimal scale.  
AJCC T-categories were codified as T1=1, T2=2, T3=3 and T4=4, to be able to 
compare the categories statistically. Actual radiation dose given was defined as: (actual 
brachytherapy duration / planned brachytherapy duration) x prescribed dose = actual dose. 
 
4.3 ETHICAL CONSIDERATIONS 
 
As all the studies have been based on retrospective data from an already existing registry and 
no changes were made to diagnostic procedures, treatment or follow-up of patients, informed 
consent was waived in accordance with the permissions from the regional ethical review 
board in Stockholm and the Swedish Ethical Review Authority. All studies adhered to the 
tenets of the declaration of Helsinki.  
To be reminded of an event that may have happened many years ago might be 
very stressful for the patient, and as the results are presented on a group level there is no way 
to identify single patients. Thus, the risk of harm to the patient has been considered higher 











5.1 PAPER I 
“High dose rate and low dose rate ruthenium brachytherapy for uveal melanoma- no 
association with ocular outcome.” 
We investigated if dose rate to the scleral surface or tumor apex correlated to the risk of 
secondary enucleation after ruthenium-106 brachytherapy of uveal melanoma. Tumor and 
patient characteristics were similar across the quartiles. As expected, thicker tumors treated 
with a standard dose to the tumor apex consequently had a lower dose rate to the tumor apex. 
There was a wide frequency distribution of both dose rate to the tumor apex (0.01-4.76 Gy/h) 
and to the scleral surface (1.66-11.11 Gy/h). Dose rate to the tumor apex was clearly skewed, 
again as expected as thinner tumors receive a higher dose per time unit to the apex. Dose rate 
to the scleral surface had a near normal distribution. 
Most patients got to keep their treated eye, the eye retention rate was 80 % 5 
years after treatment and 72 % 10 years after treatment. When secondary enucleation did 
occur, 75 % of these were due to tumor progression and the rest due to extensive damage to 
ocular tissue which could lead to secondary glaucoma, optic neuropathy, radiation 
retinopathy and other negative conditions that caused a blind and/or painful eye. Enucleation 
only because of the patients wish was rare.  
No statistical difference between the quartiles could be detected in Kaplan-
Meier survival curves neither when analyzing dose rate at the tumor apex or dose rate at the 
scleral surface. In univariate analysis, independently predictive clinical parameters of 
secondary enucleation were tumor diameter, tumor thickness and distance to the optic disc, 
but in further multivariate analysis only tumor diameter was statistically significant 
(p=0.049). There were no significant correlations between high or low dose rate and the risk 
of secondary enucleation, neither at the scleral surface nor at the tumor apex.  
 
5.2 PAPER II 
“Ruthenium-106 versus iodine-125 plaque brachytherapy of 571 choroidal melanomas with 
a thickness of ≥5.5 mm.” 
Of 571 patients, 317 (56 %) were treated with ruthenium-106. The mean apex dose was 91.6 
Gy for ruthenium-106, as expected a higher mean dose than for iodine-125, which was 81.4 
Gy, and the difference was statistically significant (p<0.001). There was also a statistically 
significant difference in tumor thickness between the groups, the mean thickness for 
ruthenium-106 treated tumors being 6.6 mm versus 8.5 mm for iodine-125 treated tumors 
(p<0.001), and the former group having a significantly better pretreatment visual acuity 
(p=0.03). There was no significant difference in rate of pre- peri- or postoperative TTT 




There was a statistically significant difference in need for a second round of 
brachytherapy (p<0.001), being 8 % (14 patients) in the ruthenium-106 group with a mean 
treatment interval of 2.2 years, and 1 % (3 patients) in the iodine-125 group with a mean 
treatment interval of 1.25 years (p=0.51). The main reason was tumor relapse for both groups, 
except for 2 ruthenium-106 treated patients who had insufficient regression. Of the 17 
patients treated twice, 8 died from metastatic disease.  
Twenty percent of the ruthenium-106 treated patients underwent secondary 
enucleation, of which 89 % was due to tumor relapse and 3% due to insufficient treatment 
effect. The remaining patients had blind eyes with or without pain. Of the iodine-125 treated 
patients, 17 % underwent secondary enucleation, of which 70 % was due to tumor relapse. 
The remaining patients had unwanted side effects like secondary glaucoma, chronic uveitis or 
total retinal detachment, except for 1 patient who preferred to have the eye enucleated.  
Multivariate Cox regression analysis with tumor diameter, tumor thickness, 
ruthenium-106 and iodine-125 as covariates revealed a significantly increasing hazard for 
secondary enucleation with increasing tumor thickness (p<0.001), but not for the other 
covariates. Overall, there was no difference in disease-specific survival between the 
radioisotopes. In the matched subgroups with tumors 5.5-7.4 mm, the mortality rate was 30 % 
and 45 % after 5- and 10-years post treatment with ruthenium-106,  and 23 % and 38% after 
iodine-125 treatment. The subgroups with tumors ≥7.5 mm had a 5- and 10-year mortality 
rate of 25 % and 51% after ruthenium-106 treatment, and 33% and 54% after iodine-125 
treatment respectively.  There were no statistically significant differences in 5- and 10-year 
survival between any of the matched subgroups.  
 
5.3 PAPER III 
“No Gender Differences in Long-Term Survival after Brachytherapy of 1,541 Patients with 
Uveal Melanoma.” 
Of the patients treated with ruthenium-106 there were 626 men and 619 women. One hundred 
and forty nine men and 147 women were treated with iodine-125. There were no statistical 
difference between men and women regarding age at diagnosis, visual acuity before 
treatment, symptom duration or type before diagnosis, which uveal structure the tumor 
originated from, AJCC T-category, radionuclide used, prescribed radiation dose, intended or 
actual treatment duration, proportion of TTT before or after brachytherapy, or follow up 
years. Tumor thickness and diameter were borderline significantly larger for men (p=0.06) 
than for women (p=0.08). The proportional hazard assumption was met in analysis of time 
from brachytherapy to death or last follow-up (p=0.83). 
The deviation from planned treatment time to actual treatment time was similar 
between men and women. There was no statistical difference in hazard ratio for disease-




categories of decreasing dose by 10 Gy where included as covariates (dose >90 Gy, 80-90 
Gy, 70-80 Gy and <70 Gy). 
One hundred and sixteen (15 %) men and 121 (16 %) women suffered from 
tumor relapse (p=0.65). Twenty-one men had brachytherapy retreatment because of tumor 
relapse (19 patients) or insufficient treatment effect (2 patients). Twenty-seven women had 
brachytherapy because of retreatment tumor relapse (24 patients) or insufficient treatment 
effect (3 patients) There was no statistically significant difference in risk of retreatment 
(p=0.36) which, if it did occur had a mean interval of 2.2 years between the treatments for 
men and a mean interval of 2.8 years for women (p=0.45). In a multivariate Cox analysis 
with tumor thickness and tumor diameter added as covariates, there was no significant 
difference in hazard ratio for repeated brachytherapy for men and women (p=0.47). Of the in 
total 48 retreated patients, 17 (35%) eventually died from metastatic disease.  
Secondary enucleation was performed on 107 (14 %) of the men and 111 (14 
%) of the women. The main reason was tumor relapse in 91 % for men and 90 % for women 
including 2 % because of insufficient treatment effect. The remaining were because of 
extensive side effects. The enucleation-free Kaplan-Meier survival was similar between men 
and women (p=0.86) and in total 33 % of the secondary enucleated patients eventually died 
from their melanoma. The median survival after diagnosis of metastatic disease of 0.9 years 
for men was not statistically different from the 1.1 years for women (p=0.12). 
The 5-year melanoma-related mortality rate for men and women were 14 % and 
15 %, and the 10-year mortality rate were 24 % and 26 % respectively. Lastly, the 15-year 
mortality rate were 27% and 32 % respectively. When adding tumor diameter and sex as 
covariates in a bi-variate Cox regression analysis, there were no significant difference in risk 
of disease-specific death between men and women (p=0.32). For men, the disease-specific 
survival was 18.2 years, and for women 15.5 years, with no statistically significant difference 
in Kaplan-Meier analysis (p=0.22). Overall survival of 13.5 years for men and 15.3 years for 
women was also similar (p=0.60). The relative risk of disease-specific death for men versus 
women was 0.9 in test of equivalence.  
 
5.4 PAPER IV 
 
“Effect of plaque brachytherapy dose and dose rate on risk for disease-related mortality in 
1238 patients with choroidal melanoma” 
 
The mean actual radiation dose ranged from 73.0 to 108.6 Gy in the first to the tenth decile, 
and the dose rate ranged from 0.5 Gy/hour to 2.8 Gy/hour. Across the deciles, symptoms and 
patient characteristics had an equal distribution for both dose and dose rate. Tumor distance 
to the macula was not equally distributed (p<0.001), being longer for lower dose and dose 
rate deciles. Distance to the optic disc was also longer for lower dose rate deciles (p=0.006), 




equally distributed. Larger tumors were more frequent in deciles with lower doses and dose 
rates, in concordance with the limited dose to the scleral surface of 1500 Gy. Iodine-125 was 
more frequent in the lower dose deciles (p<0.001) since the dose aim to the tumor apex is 80 
Gy for iodine-125 and 100 Gy for ruthenium-106. Regarding dose rate ruthenium-106 was 
the radionuclide more frequent in the high and low deciles and iodine-125 in the middle 
groups (p<0.001). Pretreatment best corrected visual acuity and treatment with TTT before 
brachytherapy were not equally distributed but did not show a certain direction of distribution 
for dose (p=0.004 and p<0.001) or dose rate (p<0.001 for both). 
 
 There was a median follow up time for metastatic-free patients of 7.5 years 
(IQR 5.8). The total mortality rate by the end of follow up was 37 % (462 patients). The 
cause of death was unknown for 18 % of these 462 patients, while 58 % had died from the 
melanoma and 24 % had died from other causes. Kaplan-Meier curves showed a significant 
difference in tumor-related mortality between high and low dose and dose rate (p<0.001), but 
in further analysis with a multivariate Cox regression analysis were tumor thickness, tumor 
diameter and distance to optic disc were added as covariates, there was no association 
between dose and melanoma-related mortality (p=0.4) or dose rate and melanoma-related 
mortality (p=0.6). For both dose and dose rate, tumor diameter was independently associated 
with melanoma-related mortality (p<0.001), but not tumor thickness (p=0.04 and p=0.07 







In Sweden, the first treatment with plaque brachytherapy for uveal melanoma was performed 
in November 1979. Ever since that very first patient, extensive data on patient and tumor 
characteristics has been continuously collected along with treatment parameters and follow-
up. As St. Erik Eye Hospital in Stockholm is the only center in the country performing the 
treatment, this registry has full coverage. Furthermore, personal identification numbers allow 
for near complete follow-up data, regardless of the patients’ region of residence. For almost 
three decades, all data was registered by one single devoted person, Professor Göran Lundell, 
and after that only a handful others, ensuring high that every involved individual has a high 
degree of insight, knowledge and professional investment in the data. These circumstances 
form the backdrop for a unique research environment that is virtually unmatched in the 
world.   
The treatment parameters collected include dosimetric aspects such as dose and 
dose rate at both the tumor base and tumor apex. Previous studies have shown that with dose 
rates that are too low, tumor cells may recover after being irradiated while dose rates that are 
too high will cause unnecessary damage to normal tissue.(Yang et al., 1993) In the first study 
included in this thesis (paper I), by analyzing the rate of secondary enucleation in relation to 
widely ranging dose rates in ruthenium-106 brachytherapy, we came to the conclusion that 
the dose rates commonly used in our practice are neither causing too much damage to normal 
surrounding ocular tissue, nor causing unacceptable rates of local recurrence. Naseripour et al 
studied 51 patients with melanomas 7-11 mm thick, treated with ruthenium-106 and found a 
lower secondary enucleation rate of 10 % than our results, however with a shorter mean 
follow up time of 3 years. Radiation dose rates to tumor apex and to the scleral surface were 
0.37 (0.23 - 0.51) Gy/h and 6.44 (5.94 – 7.94) Gy/h respectively.(Naseripour et al., 2016) 
Mossböck et al reported in a small number of patients a significantly lower metastatic rate in 
patients treated with plaques with calculated dose rates > 4 Gy/h than patients treated with 
plaques less than 4 Gy/h.(Mossbock, Rauscher, Winkler, Kapp, & Langmann, 2007). The 
absence of data on dose rate at the tumor apex or scleral surface however makes comparison 
challenging. One must also take into account that differing results in eye retention rate is 
influenced by what is traditionally recommended in each clinic, in case of local recurrence – 
retreatment or secondary enucleation.   
As ruthenium-106 was the only radionuclide used in our center between 1979 
and1999, we had an opportunity to compare ruthenium-106 and iodine-125 treatment for 
thicker tumors than 5.5 mm in subgroups matched regarding patient demographics and 
clinical features, paper II. We found no significant differences in risk of secondary 
enucleation or of melanoma-related death in contrast to Tagliaferri et al. who found a 
significantly higher rate of metastatic disease after treatment with ruthenium-106 compared to 
iodine-125 in patients with tumors 5-7 mm thick, but no difference in local control, albeit 
only in 26 patients.(Tagliaferri et al., 2012) We did however find that ruthenium-106 




retreatment than iodine-125 brachytherapy. This alone we consider sufficient reason to avoid 
ruthenium-106 for thicker tumors. The reason for retreatment is local recurrence and 
occasionally insufficient regression. Even if we found no such relation in our study, local 
recurrence has been associated with higher risk of metastatic disease in a large multicenter 
study by the Ophthalmic Oncology Task Force.(Ophthalmic Oncology Task, 2016) In this 
context, it should however be mentioned that the prognostic implications of tumor recurrence 
may be caused by the fact that aggressive tumors recur more often, rather than that 
insufficient brachytherapy cause increased aggressiveness. Consistent with our findings in 
both paper I and II, Papageorgiou et al. didn’t find a correlation between dose rate and risk of 
local recurrence, but indeed a higher risk for local recurrence for tumors >5 mm thick treated 
with ruthenium-106.(Papageorgiou, Cohen, Bunce, Kinsella, & Hungerford, 2011) Tarmann 
et al. analyzed 30 patients with tumors >7 mm thick that received ruthenium-106 treatment, 
and found a significant correlation to secondary enucleation but not to tumor 
recurrence.(Tarmann et al., 2015) Again, differing results are influenced by local decisions on 
retreatment versus secondary enucleation in cases of tumor relapse. Not least, avoidance of 
retreatment is of course desirable for the patient and also for economic and health care 
reasons.  
For thinner tumors, ruthenium-106 seems to be a better treatment choice. It 
has a high local control rate,(B. Damato, Patel, et al., 2005; Takiar et al., 2015) and its 
preferred usage for thinner tumors is supported by the findings by Takiar et al, who found  a 
significantly higher risk of unwanted side effects when comparing iodine-125 against 
ruthenium-106 for tumors <5 mm thick.(Takiar et al., 2015)  
As described earlier, men have been reported to have larger tumors than women 
at presentation. (B. E. Damato & Coupland, 2012) In addition, men have been reported to 
have a higher frequency and earlier debut of metastatic disease than women, (Zloto, Pe'er, & 
Frenkel, 2013) and also a shorter survival rate after the diagnosis of metastatic disease. 
(Rietschel et al., 2005) In paper III we analyzed tumor and treatment parameters in relation to 
gender, as far as we know not investigated before from a treatment perspective. We found no 
significant differences between men and women in survival or ocular outcomes that would 
indicate that the treatment strategy should be adjusted in any way depending on the patient’s 
sex.  
 The dose of 85 Gy to the tumor apex, at least for iodine-125, has traditionally 
been accepted since the COMS trials, and in the same time period our clinic lowered the apex 
dose from 100 Gy to 80 Gy for iodine-125, i.e 5 Gy lower than the American Brachytherapy 
Society’s recommendations. Throughout the years, the great majority of patients have 
received the intended dose, but for natural reasons, final doses have been lower and higher 
than prescribed in some cases. In paper IV we found no adverse effects on treatment 
effectivity or side effects from a dose range of 73-108 Gy. This finding is in concordance 
with Perez et al. who did not find lower rates of local control, survival, metastases with 
iodine-125 doses down to 63-69 Gy to the apex. They did however note significantly worse 
visual acuity and radiation complications with higher doses up to 104 Gy (Perez et al., 2014) 




studies by Echegaray et al. who also concluded that there are no certain relation between 
local recurrence and lower iodine-125 doses to the apex, opening up for randomized trials 
investigating this further.(Echegaray, Bechrakis, Singh, Bellerive, & Singh, 2017) Quivey et 
al found a correlation between lower dose and dose rate to the tumor apex, lower dose rate to 
the base, long treatment duration and increased risk of local failure when analyzing 150 
patients treated with iodine-125 retrospectively, however treatment dose to the tumor apex 
ranged all the way down to 29.5 Gy.(Quivey, Augsburger, Snelling, & Brady, 1996)  
 In our study we included both ruthenium-106 and iodine-125, a decision based 
on our finding in paper II, that the use of ruthenium-106 or iodine-125 is not an independent 
predictor of melanoma-related death.  
The fact that uveal melanoma can metastasize decades after primary treatment 
raises concerns that it doesn’t really matter how and if we try to treat the tumor. However, it 
is well known that larger tumors carry a worse prognosis.(Arnljots et al., 2018; Shields, 
Furuta, Thangappan, et al., 2009; Shields, Kaliki, Furuta, et al., 2015) It has also been shown 
that older age at treatment is associated with worse prognosis and most risk factors for tumor 
spread. As the mean tumor diameter is larger for older patients, and larger tumors carry a 
higher degree of for example monosomy 3, earlier treatment prevents not only local tumor 
growth but also negative genetic alterations, dedifferentiation and metastatic spread.(B. E. 
Damato, Heimann, Kalirai, & Coupland, 2014)  Over the last years the importance of tumor 
surrounding microenvironment for the metastatic process has been paid more and more 
attention. Uveal melanoma primary tumors which express a high level of immune 
checkpoints T cell Ig and ITIM domain (TIGIT) and indoleamine 2,3-dioxygenase (IDO) 
carry a higher risk of metastatic spread,(Robertson et al., 2017; Stalhammar, Seregard, & 
Grossniklaus, 2019) as well as tumors with a high rate of infiltrating macrophages and a 
dense extracellular matrix, (Makitie, Summanen, Tarkkanen, & Kivela, 2001; Stalhammar, 
See, Phillips, & Grossniklaus, 2019) all of which have more time and opportunity to develop 
in the happening of insufficient and/or late treatment. That being said, brachytherapy for 
uveal melanoma is a necessary treatment and our findings support that lower treatment doses 






Uveal melanoma is a rare cancer, but still the most common primary malignant intraocular 
tumor in adults. The prognosis is similar after enucleation and eye-preserving plaque 
brachytherapy. A high proportion of patients develop metastases, after which the prognosis is 
dismal. 
Plaque brachytherapy of uveal melanoma with ruthenium-106 and iodine-125 is 
well established and these radionuclides are widely used in most developed countries. The 
aim of this thesis was to analyze different aspects of brachytherapy of uveal melanoma and its 
correlation with ocular and patient outcomes. Both radionuclides have their place in the 
treatment regime, with ruthenium-106 being more advantageous for thinner tumors and 
iodine-125 for thicker tumors. The current dose and dose rate recommendations are effective 
but our findings support that lower doses and dose rates are also safe and effective, which 
opens up for further investigation in randomized trials. We found no indications that the 
patient’s gender needs to be taken into account when planning the brachytherapy treatment, 





8 POINTS OF PERSPECTIVE 
 
The introduction of brachytherapy as a treatment alternative for uveal melanoma has meant a 
sight preserving alternative for countless patients. In the initial era of brachytherapy, 
treatment was based mainly on consensus. Increasing number of studies analyzing the 
optimal radionuclide, dose and dose rate as well as which patient features and genetic aspects 
are most relevant for outcome, takes us further and further towards optimizing the 
brachytherapy treatment for each individual patient. To be able to tell the patients that we are 
giving the best treatment available not only based on experience, but also based on extensive 
research, is of essence. 
My studies are retrospective and not randomized. Even if a prospective 
randomized trial is always preferable, the large number of patients that we are able to analyze 
in our extensive BRUM directory reaching four decades back, makes our findings a very high 
powered valuable contribution to the knowledge about uveal melanoma and brachytherapy 
we have today. 
 Hopefully, one day brachytherapy will be a treatment that was used in the past. 
Hopefully, as we understand more and more of the molecular pathways and the genetics of 
uveal melanoma, a tumor specific treatment effective on both primary tumor and 
micrometastases, not harmful for normal tissue, will become a reality. Until then, plaque 
brachytherapy will be a mainstay in uveal melanoma treatment and consequently, further 
studies in the field of brachytherapy in parallel with studies of uveal melanoma on a 
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